Myelodysplastic syndromes

Myelodysplastic syndromes

Myelodysplastic syndromes

On this page

MDS Intro - The Failing Factory

  • Clonal hematopoietic stem cell disorders causing ineffective hematopoiesis (a dysfunctional bone marrow factory).
  • Leads to peripheral cytopenias (anemia, neutropenia, thrombocytopenia) despite a normo- or hypercellular marrow.
  • Hallmark is dysplasia (abnormal cell morphology) in one or more myeloid lineages.
  • Considered a pre-leukemic condition with risk of transformation to Acute Myeloid Leukemia (AML), defined by ≥20% blasts.

⭐ The central paradox of MDS is a hypercellular, "packed" bone marrow that yields peripheral cytopenias due to defective, apoptotic cells.

Pseudo-Pelger-Huët neutrophil and dyserythropoiesis in MDS

Pathophysiology - Corrupted Blueprints

  • Clonal mutation in a hematopoietic stem cell (HSC) is the primary insult.
  • Leads to ineffective hematopoiesis: marrow is hypercellular but cells are defective (dysplastic) and undergo apoptosis.
    • Results in peripheral blood cytopenias (anemia, neutropenia, thrombocytopenia).
    • Dysplastic changes visible in one or more cell lines (e.g., pseudo-Pelger-Huët cells, ring sideroblasts).
  • Represents a pre-malignant state with a high risk of transformation to Acute Myeloid Leukemia (AML).

MDS: Dysplastic megakaryocytes and erythroid precursors

MDS with isolated del(5q) is a unique subtype with a favorable prognosis, often presenting with thrombocytosis, and showing a robust response to lenalidomide therapy.

Diagnosis & Features - Spotting the Sabotage

  • Complete Blood Count (CBC):
    • Hallmark: Unexplained, persistent cytopenia(s), especially macrocytic anemia (↑ MCV).
  • Peripheral Blood Smear:
    • Shows dysplastic features in ≥1 cell line.
    • WBCs: Pseudo-Pelger-Huët cells (bilobed nuclei).
    • RBCs: Ovalomacrocytes.
    • Platelets: Giant or hypogranular platelets.
  • Bone Marrow Aspirate & Biopsy (Definitive Dx):
    • Hypercellular marrow despite peripheral cytopenias.
    • Dysplasia in ≥10% of cells in a lineage.
    • Key: Myeloblasts < 20%.

⭐ A blast count of ≥ 20% in the bone marrow or blood signifies transformation to Acute Myeloid Leukemia (AML).

  • Hallmark: Ineffective hematopoiesis → peripheral cytopenias despite a hypercellular or normocellular bone marrow.
  • Key Feature (Dyspoiesis): Abnormal maturation in ≥1 cell line.
    • Erythroid: Ring sideroblasts (>15% of precursors), megaloblastoid changes, nuclear budding.
    • Myeloid: Pseudo-Pelger-Huët cells (bilobed nuclei), hypogranulation.
    • Megakaryocytic: Micromegakaryocytes, "pawnball" nuclei (small, non-lobated).
  • Blasts: Bone marrow blasts are < 20%; reaching this threshold signifies transformation to AML.

Pseudo-Pelger-Huët cell and ring sideroblasts in MDS

MDS with isolated del(5q): Typically affects older women, presenting with macrocytic anemia, a normal or elevated platelet count, and carrying a favorable prognosis.

Prognosis & Treatment - Damage Control

  • Prognosis: Stratified by the IPSS-R score, which predicts survival and AML transformation risk. Key factors include marrow blast %, cytogenetics, and severity of cytopenias.
  • Supportive Care (Damage Control): The mainstay for lower-risk MDS, focused on managing marrow failure.
    • Anemia: RBC transfusions for symptoms; ESAs if serum EPO is <500 U/L.
    • Thrombocytopenia: Platelet transfusions for active bleeding.
    • Neutropenia: G-CSF for recurrent infections.
    • Iron Overload: Iron chelation for patients with chronic transfusion needs.

⭐ Isolated del(5q) syndrome is a unique entity with a favorable prognosis and high response rates to lenalidomide.

High‑Yield Points - ⚡ Biggest Takeaways

  • Clonal stem cell disorders in the elderly, leading to ineffective hematopoiesis and peripheral cytopenias.
  • Hallmark is dysplasia in one or more myeloid lineages, such as pseudo-Pelger-Huët cells and ring sideroblasts.
  • Bone marrow is paradoxically hypercellular despite low peripheral blood counts.
  • Patients often present with a macrocytic anemia (↑ MCV) resistant to standard therapies.
  • Carries a high risk of progression to Acute Myeloid Leukemia (AML).
  • The del(5q) syndrome subtype has a more favorable prognosis and often responds to lenalidomide.

Practice Questions: Myelodysplastic syndromes

Test your understanding with these related questions

A 45-year-old woman comes to the physician because of a 1-week history of fatigue and bruises on her elbows. Examination shows a soft, nontender abdomen with no organomegaly. Laboratory studies show a hemoglobin concentration of 7 g/dL, a leukocyte count of 2,000/mm3, a platelet count of 40,000/mm3, and a reticulocyte count of 0.2%. Serum electrolyte concentrations are within normal limits. A bone marrow biopsy is most likely to show which of the following findings?

1 of 5

Flashcards: Myelodysplastic syndromes

1/5

Myeloproliferative disorders may progress to marrow _____ or transform to acute leukemia

TAP TO REVEAL ANSWER

Myeloproliferative disorders may progress to marrow _____ or transform to acute leukemia

fibrosis

browseSpaceflip

Enjoying this lesson?

Get full access to all lessons, practice questions, and more.

Start Your Free Trial